202138-50-9 in stock bulk tenofovir TDF cheap

Min.Order / FOB Price:Get Latest Price

1 Kilogram	Negotiable

1 Kilogram

Negotiable

Min.Order :1 Kilogram
Purity: 98.0%~102.0% (on anhydrous basis)
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

202138-50-9 in stock TDF bulk tenofovir TDF cheap

Quick Details

Appearance:White to off-white crystalline powder
Application:HIV, HBV
PackAge:Two-layer LDPE bag and All Paper Drum
ProductionCapacity:200|Metric Ton|Year
Storage:2~8°C.
Transportation:as per request

Superiority:

202138-50-9 in stock bulk tenofovir TDF cheap

LONZEAL Pharmaceuticals was founded in 2006 and has become a leading manufacturing company covering finished formulation, active pharmaceutical ingredients and advanced intermediates, where ICH guidelines have been strictly applied in the whole chain of R&D, manufacturing process and quality management.
LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.
We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.
Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.

Details:

1. It is contraindicated for tenofovir or allergy to this product.

2. There are not enough well-controlled clinical studies for pregnant women, which should be used only when clearly needed by pregnant women.

3. This product can be discharged through milk, and HIV-infected persons should not breastfeed, in order to avoid virus transmission through milk and harm to the fetus caused by this product.

4. The safety and efficacy of hepatitis B for children under 12 years of age have not yet been determined.

Matters needing attention

Osteomalacia (associated with proximal renal tubular lesions) has been reported to be associated with this product, and bone monitoring should be considered in hiv-infected patients with pathological fractures or at risk for osteosclerosis. Although no studies have been conducted on the effects of calcium and vitamin D supplements, such supplements may be beneficial for all patients.

View All

Visit Store